Advisors Asset Management’s BridgeBio Pharma BBIO Stock Holding History

Advisors Asset Management’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$612K	Sell	8,223 -2,742	-25%	-$192K	0.01%	947
2026 Q1	$814K	Sell	10,965 -1,557	-12%	-$113K	0.01%	849
2025 Q4	$958K	Sell	12,522 -134	-1%	-$8.8K	0.02%	799
2025 Q3	$657K	Sell	12,656 -47	-0.4%	-$2.29K	0.01%	912
2025 Q2	$549K	Buy	12,703 +3	+0%	+$109	0.01%	926
2025 Q1	$439K	Buy	12,700 +3,687	+41%	+$124K	0.01%	965
2024 Q4	$247K	Buy	9,013 +4,437	+97%	+$115K	﹤0.01%	1085
2024 Q3	$117K	Buy	4,576 +1,645	+56%	+$43.2K	﹤0.01%	1198
2024 Q2	$74.2K	Buy	+2,931	New	+$80.1K	﹤0.01%	1238

Other funds holding BBIO

Jupiter Topco New York $245B AUM

KKRC

Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Advisors Asset Management's BBIO Position: Q2 2026 in Review

Advisors Asset Management reduced its BridgeBio Pharma (BBIO) stake by 25% in Q2 2026, selling an estimated $192K and leaving 8,223 shares worth $612K. The position accounts for 0.01% of the portfolio, ranked #947.

Advisors Asset Management first reported a position in BBIO in Q2 2024 and has held it in 9 quarters since. The position peaked at $958K in Q4 2025. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

Advisors Asset Management held 8,223 shares of BridgeBio Pharma worth $612K as of Q2 2026.
Advisors Asset Management sold 2,742 BridgeBio Pharma shares in Q2 2026, an estimated $192K.
BridgeBio Pharma made up 0.01% of Advisors Asset Management's portfolio in Q2 2026, its #947 holding.
Advisors Asset Management first reported a position in BridgeBio Pharma in Q2 2024 and has held it in 9 quarters since.
Advisors Asset Management's BridgeBio Pharma position peaked at $958K in Q4 2025.
474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Advisors Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.